NTRK1 and chronic myelogenous leukemia, BCR-ABL1 positive: As a member of the receptor tyrosine kinase family, c-Kit is involved in diverse cellular functions, such as differentiation, apoptosis, and survival.35 The c-Kit inhibitor imatinib was the first drug approved by the United States Food and Drug Administration for targeted therapy,26 and it is now widely used to treat gastrointestinal stromal tumor (GIST), chronic myeloid leukemia, and other cancers.